{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:07:12Z","timestamp":1791184032758,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"DOI":"10.1038\/cddis.2013.318","type":"journal-article","created":{"date-parts":[[2013,9,19]],"date-time":"2013-09-19T13:00:49Z","timestamp":1379595649000},"page":"e808-e808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis"],"prefix":"10.1038","volume":"4","author":[{"given":"Z","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Caja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Melino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T S","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Lindfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,19]]},"reference":[{"key":"BFcddis2013318_CR1","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1158\/1078-0432.CCR-11-0659","volume":"17","author":"C Lieu","year":"2011","unstructured":"Lieu C, Heymach J, Overman M, Tran H, Kopetz S . Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 2011; 17: 6130\u20136139.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2013318_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-3-540-78281-0_7","volume":"180","author":"C Hellberg","year":"2010","unstructured":"Hellberg C, Ostman A, Heldin CH . PDGF and vessel maturation. Recent Results Cancer Res 2010; 180: 103\u2013114.","journal-title":"Recent Results Cancer Res"},{"key":"BFcddis2013318_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000320006","volume":"46","author":"MJ Siemerink","year":"2010","unstructured":"Siemerink MJ, Augustin AJ, Schlingemann RO . Mechanisms of ocular angiogenesis and its molecular mediators. Dev Ophthalmol 2010; 46: 4\u201320.","journal-title":"Dev Ophthalmol"},{"key":"BFcddis2013318_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1586\/era.09.6","volume":"9","author":"RS Finn","year":"2009","unstructured":"Finn RS, Zhu AX . Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 2009; 9: 503\u2013509.","journal-title":"Expert Rev Anticancer Ther"},{"key":"BFcddis2013318_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/157488408784293705","volume":"3","author":"JM Roodhart","year":"2008","unstructured":"Roodhart JM, Langenberg MH, Witteveen E, Voest EE . The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway. Curr Clin Pharmacol 2008; 3: 132\u2013143.","journal-title":"Curr Clin Pharmacol"},{"key":"BFcddis2013318_CR6","first-page":"7282","volume":"61","author":"U Graeven","year":"2001","unstructured":"Graeven U, Rodeck U, Karpinski S, Jost M, Philippou S, Schmiegel W . Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res 2001; 61: 7282\u20137290.","journal-title":"Cancer Res"},{"key":"BFcddis2013318_CR7","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1042\/bj20021234","volume":"368","author":"M Griffin","year":"2002","unstructured":"Griffin M, Casadio R, Bergamini CM . Transglutaminases: nature\u2019s biological glues. Biochem J 2002; 368: 2002.","journal-title":"Biochem J"},{"key":"BFcddis2013318_CR8","doi-asserted-by":"publisher","first-page":"40212","DOI":"10.1074\/jbc.M110.123703","volume":"285","author":"Z Wang","year":"2010","unstructured":"Wang Z, Collighan RJ, Gross SR, Danen EH, Orend G, Telci D et al. RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4\/2 and {alpha}5{beta}1 integrin co-signaling. J Biol Chem 2010; 285: 40212\u201340229.","journal-title":"J Biol Chem"},{"key":"BFcddis2013318_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00726-011-1214-6","volume":"44","author":"RA Jones","year":"2013","unstructured":"Jones RA, Wang Z, Dookie S, Griffin M . The role of TG2 in ECV304-related vasculogenic mimicry. Amino Acids 2013; 44: 89\u2013101.","journal-title":"Amino Acids"},{"key":"BFcddis2013318_CR10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1290\/1071-2690(2001)037<0505:PCOHUV>2.0.CO;2","volume":"37","author":"K Suda","year":"2001","unstructured":"Suda K, Rothen-Rutishauser B, Gunthert M, Wunderli-Allenspach H . Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features. In Vitro Cell Dev Biol Anim 2001; 37: 505\u2013514.","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"BFcddis2013318_CR11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.ejmech.2013.05.018","volume":"66","author":"E Badarau","year":"2013","unstructured":"Badarau E, Mongeot A, Collighan R, Rathbone D, Griffin M . Imidazolium-based warheads strongly influence activity of waster-soluble peptidic transglutmainase inhibitors. Eur J Med Chem 2013; 66: 526\u2013530.","journal-title":"Eur J Med Chem"},{"key":"BFcddis2013318_CR12","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.1016\/j.bmcl.2008.09.006","volume":"18","author":"M Griffin","year":"2008","unstructured":"Griffin M, Mongeot A, Collighan R, Saint RE, Jones RA, Coutts IG et al. Synthesis of potent water-soluble tissue transglutaminase inhibitors. Bioorg Med Chem Lett 2008; 18: 5559\u20135562.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFcddis2013318_CR13","doi-asserted-by":"publisher","first-page":"10109","DOI":"10.1021\/bi00199a039","volume":"33","author":"KF Freund","year":"1994","unstructured":"Freund KF, Doshi KP, Gaul SL, Claremon DA, Remy DC, Baldwin JJ et al. Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry 1994; 33: 10109\u201310119.","journal-title":"Biochemistry"},{"key":"BFcddis2013318_CR14","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/sj.cdd.4401816","volume":"13","author":"RA Jones","year":"2006","unstructured":"Jones RA, Kotasakis P, Johnson TS, Chau DY, Ali S, Melino G et al. Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ 2006; 13: 1442\u20131453.","journal-title":"Cell Death Differ"},{"key":"BFcddis2013318_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/emmm.201000084","volume":"2","author":"SJ McConoughey","year":"2010","unstructured":"McConoughey SJ, Basso M, Niatsetakays ZV, Sleiman SF, Smirnova NA, Langley BC et al. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med 2010; 2: 349\u2013370.","journal-title":"EMBO Mol Med"},{"key":"BFcddis2013318_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1023\/A:1026546219962","volume":"3","author":"ET Bishop","year":"1999","unstructured":"Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NF, Wheatley DN . An in vitro model of angiogenesis: basic features. Angiogenesis 1999; 3: 335\u2013344.","journal-title":"Angiogenesis"},{"key":"BFcddis2013318_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1083\/jcb.200703036","volume":"179","author":"JD Humphries","year":"2007","unstructured":"Humphries JD, Wang P, Streuli C, Geiger B, Humphries MJ, Ballestrem C . Vinculin controls focal adhesion formation by direct interactions with talin and actin. J Cell Biol 2007; 179: 1043\u20131057.","journal-title":"J Cell Biol"},{"key":"BFcddis2013318_CR18","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.yexcr.2009.03.017","volume":"315","author":"S Fernandez-Sauze","year":"2009","unstructured":"Fernandez-Sauze S, Grall D, Cseh B, Van Obberghen-Schilling E . Regulation of fibronectin matrix assembly and capillary morphogenesis in endothelial cells by Rho family GTPases. Exp Cell Res 2009; 315: 2092\u20132104.","journal-title":"Exp Cell Res"},{"key":"BFcddis2013318_CR19","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1096\/fasebj.13.13.1787","volume":"13","author":"ZA Haroon","year":"1999","unstructured":"Haroon ZA, Hettasch JM, Lai TS, Dewhirst MW, Greenberg CS . Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J. 1999; 13: 1787\u20131795.","journal-title":"FASEB J."},{"key":"BFcddis2013318_CR20","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00109-011-0853-0","volume":"90","author":"S Martucciello","year":"2012","unstructured":"Martucciello S, Lavric M, Toth B, Korponay-Szabo I, Nadalutti C, Myrsky E et al. RhoB is associated with the anti-angiogenic effects of celiac patient transglutaminase 2-targeted autoantibodies. J Mol Med 2012; 90: 817\u2013826.","journal-title":"J Mol Med"},{"key":"BFcddis2013318_CR21","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1242\/jcs.114.15.2755","volume":"114","author":"SE Bell","year":"2011","unstructured":"Bell SE, Mavila A, Salazar R, Bayless KJ, Kanagala S, Maxwell SA et al. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J Cell Sci 2011; 114: 2755\u20132773.","journal-title":"J Cell Sci"},{"key":"BFcddis2013318_CR22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1042\/BJ20091594","volume":"427","author":"C Faye","year":"2010","unstructured":"Faye C, Inforzata A, Bignon M, Hartmann DJ, Muller L, Ballut L et al. Transglutaminase-2: a new endostatin partner in the extracellular matrix of endothelial cells. Biochem J 2010; 427: 467\u2013475.","journal-title":"Biochem J"},{"key":"BFcddis2013318_CR23","doi-asserted-by":"publisher","first-page":"13063","DOI":"10.1074\/jbc.M111.294819","volume":"287","author":"Z Wang","year":"2012","unstructured":"Wang Z, Collighan RJ, Pytel K, Rathbone DL, Li X, Orend G et al. Characterization of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signaling. J Biol Chem 2012; 287: 13063\u201313083.","journal-title":"J Biol Chem"},{"key":"BFcddis2013318_CR24","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00726-011-1008-x","volume":"42","author":"Z Wang","year":"2012","unstructured":"Wang Z, Griffin M . TG2, a novel extracellular protein with multiple functions. Amino Acids 2012; 42: 939\u2013949.","journal-title":"Amino Acids"},{"key":"BFcddis2013318_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1152\/physrev.00044.2008","volume":"89","author":"SE Iismaa","year":"2009","unstructured":"Iismaa SE, Mearns BM, Lorand L, Graham RM . Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev 2009; 89: 991\u20131023.","journal-title":"Physiol Rev"},{"key":"BFcddis2013318_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00726-011-1183-9","volume":"44","author":"S Deasey","year":"2013","unstructured":"Deasey S, Shanmugasundaram S, Nurminskaya M . Tissue-specific responses to loss of transglutaminase 2. Amino Acids 2013; 44: 179\u2013187.","journal-title":"Amino Acids"},{"key":"BFcddis2013318_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.imlet.2009.07.009","volume":"126","author":"B Toth","year":"2009","unstructured":"Toth B, Sarang Z, Vereb G, Zhang AL, Tanaka S, Melino G et al. Over-expression of integrin beta 3 can partially overcome the defect of integrin beta 3 signaling in transglutaminase 2 null macrophages. Immunol Lett 2009; 126: 22\u201328.","journal-title":"Immunol Lett"},{"key":"BFcddis2013318_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1083\/jcb.148.4.825","volume":"148","author":"SS Akimov","year":"2000","unstructured":"Akimov SS, Krylov D, Fleischman LF, Belkin AM . Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol 2000; 148: 825\u2013838.","journal-title":"J Cell Biol"},{"key":"BFcddis2013318_CR29","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1016\/j.febslet.2006.03.087","volume":"580","author":"H Roy","year":"2006","unstructured":"Roy H, Bhardwaj S, Yla-Herttuala S . Biology of vascular endothelial growth factors. FEBS Lett 2006; 580: 2879\u20132887.","journal-title":"FEBS Lett"},{"key":"BFcddis2013318_CR30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1083\/jcb.200906044","volume":"188","author":"TT Chen","year":"2010","unstructured":"Chen TT, Juque A, Lee S, Anderson SM . Segura and Iruela-Arispe ML. Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells. J Cell Biol 2010; 188: 595\u2013609.","journal-title":"J Cell Biol"},{"key":"BFcddis2013318_CR31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10456-011-9220-6","volume":"14","author":"RR Mehta","year":"2011","unstructured":"Mehta RR, Yamada T, Taylor BN, Christov K, King ML, Majumdar D et al. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt. Angiogenesis 2011; 14: 355\u2013369.","journal-title":"Angiogenesis"},{"key":"BFcddis2013318_CR32","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1002\/jcp.22468","volume":"226","author":"E Karaoz","year":"2011","unstructured":"Karaoz E, Okcu A, Gacar G, Saglam O, Yurucker S, Kenar H . A comprehensive characterization study of human bone marrow mscs with an emphasis on molecular and ultrastructural properties. J Cell Physiol 2011; 226: 1367\u20131382.","journal-title":"J Cell Physiol"},{"key":"BFcddis2013318_CR33","doi-asserted-by":"publisher","first-page":"e16665","DOI":"10.1371\/journal.pone.0016665","volume":"6","author":"G Colak","year":"2011","unstructured":"Colak G, Keillor JW, Johnson GV . Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation. PLoS ONE 2011; 6: e16665.","journal-title":"PLoS ONE"},{"key":"BFcddis2013318_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0076-6879(08)02005-3","volume":"443","author":"W Koh","year":"2008","unstructured":"Koh W, Stratman AN, Sacharidou A, Davis GE . In vitro three dimensional collagen matrix models of endothelial lumen formation during vasculogenesis and angiogenesis. Methods Enzymol 2008; 443: 83\u2013101.","journal-title":"Methods Enzymol"},{"key":"BFcddis2013318_CR35","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00726-010-0790-1","volume":"41","author":"P Kotsakis","year":"2011","unstructured":"Kotsakis P, Wang Z, Collighan RJ, Griffin M . The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26. Amino Acids 2011; 41: 909\u2013921.","journal-title":"Amino Acids"},{"key":"BFcddis2013318_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1023\/A:1021509004829","volume":"5","author":"W Zhu","year":"2002","unstructured":"Zhu W, Nicosia RF . The thin prep rat aortic ring assay: a modified method for the characterization of angiogensis in whole mounts. Angiogenesis 2002; 5: 81\u201386.","journal-title":"Angiogenesis"},{"key":"BFcddis2013318_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0076-6879(08)02802-4","volume":"444","author":"EI Deryugina","year":"2008","unstructured":"Deryugina EI, Quigley JP . Chick embryo chorioallantoic membrane models to quantify angiogenesis induced by inflammatory and tumor cells or purified effector molecules Chapter 2 Methods Enzymol 2008; 444: 21\u201341.","journal-title":"Methods Enzymol"}],"updated-by":[{"DOI":"10.1038\/s41419-026-08821-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000}}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis2013318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:37:47Z","timestamp":1778686667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2013318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,19]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,9]]}},"alternative-id":["BFcddis2013318"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2013.318","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,19]]},"assertion":[{"value":"10 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41419-026-08821-y","URL":"https:\/\/doi.org\/10.1038\/s41419-026-08821-y","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}